Company / Net Debt per Share
Inhibrx Biosciences, Inc. Net Debt per Share History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Debt per Share
-$1.63
FY2025
5-year range
-$6.02 / -$1.63
FY2023-FY2025
Trend
+49.3%
vs FY2024
Sector context
#63 of 82
Health Care
What the data says
Inhibrx Biosciences, Inc.'s net debt per share of $-1.63 is lower than 77% of companies in the Health Care sector (FY2025). Increased from $-6.02 to $-1.63 over the past 2 years.
Based on SEC 10-K filings.
-1.63 in FY2025.
Increased from $-6.02 to $-1.63 over the past 2 years.
Health Care sector context is included.
Net Debt per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 23% in Health CareTop 23% of 82This company -$1.63 Sector average $13.70
▼
-111.9% below sector average
Key checks
Key Insights
- In FY2025, net debt per share increased 49.3% year-over-year.
- Ranks #63 out of 82 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.63 | +49.3% |
| FY2024 | -$3.22 | +46.5% |
| FY2023 | -$6.02 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026